Vectura sales trigger $5m milestone receipt
25th Jan 2017 07:48
(ShareCast News) - Vectura said on Wednesday that a sales milestone receipt of $5m has been triggered following confirmation by Novartis that EU/Rest of World combined net sales of its Seebri Breezhaler and Ultibro Breezhaler for the year to the end of December have reached $512m. The milestone will
Read moreVectura gets FDA investigational approval for VR647
24th Jan 2017 08:21
(ShareCast News) - Device and formulation business for inhaled airways disease, Vectura Group, announced on Tuesday it has received an 'Investigational New Drug' approval from the US Food and Drug Administration for its VR647 product. The FTSE 250 firm said the approval will allow it to conduct a Ph
Read moreVectura makes 'significant progess' in third quarter
11th Jan 2017 08:25
(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced an unaudited pre-close update on Wednesday, ahead of its results for the nine months to 31 December, due in March. The FTSE 250 company said that following the step-change in financial performance anno
Read moreVectura Group signs development agreement with Mundipharma
23rd Dec 2016 07:57
(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced on Friday that it has signed a development and licence agreement with Mundipharma International Corporation and a US independent associated company as the global development and commercialisation partn
Read moreVectura says Bayer completes EU approval procedure for alternative nebulised delivery
22nd Dec 2016 14:57
(ShareCast News) - Vectura said on Thursday that its partner Bayer has confirmed completion of the EU regulatory procedure that allows an alternative nebulised delivery for its currently-marketed product Ventavis using the London-listed company's smart nebuliser Fox device. Ventavis has been develop
Read moreVectura says Novartis signs US licensing agreement for COPD treatments
21st Dec 2016 14:15
(ShareCast News) - Vectura announced that Swiss pharmaceutical company Novartis has signed a licensing agreement with Sunovion Pharmaceuticals for the US commercialisation rights to three treatments for chronic obstructive pulmonary disease for which it receives royalty revenues. Novartis, whose pro
Read moreVectura confirms positive study results for Ultibro Breezhaler
8th Dec 2016 07:57
(ShareCast News) - Inhaled airways disease-focused business Vectura Group confirmed an announcement by its partner Novartis on Thursday. The FTSE 250 firm said the announcement was of positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequ
Read moreVectura earnings surge as Skyepharma merger creates step-change
23rd Nov 2016 07:40
(ShareCast News) - Inhaler maker Vectura's interim revenue have soared following the merger with rival Skyepharma and a launch of new products. For the six months ended 30 September, revenue increased 183% to £73.9m, compared to the same period last year, primarily due to the completion of the £441m
Read moreSunday newspaper round-up: OBR, Saudi Aramco, Tesco, BAT, bonds vigilantes
20th Nov 2016 15:57
(ShareCast News) - The Office for Budget Responsibility is likely to cut its forecast for UK growth next year by the biggest margin since the peak of the eurozone debt crisis. Philip Hammond's Autumn Statement this week will see the Chancellor set out his multi-billion pound infrastructure plans and
Read moreVectura climbs on positive read-across from Novartis, Singer upgrade
26th Oct 2016 14:14
(ShareCast News) - Shares in medical device group Vectura were given a boost by expectations of foreign currency gains and investors reading across results from Novartis, with which the London-listed company is partnered on a handful of products. A third-quarter update from Novartis on Tuesday in
Read moreVectura Group gains from Skyepharma merger as it raises expectations
7th Sep 2016 08:09
(ShareCast News) - Inhaled airways disease focused business Vectura Group raised expectations for 2016 as it said it is making progress with the June Skyepharma merger. The company raised revenue expectations for the nine month period ended 31 December, due to strong growth from its partnered market
Read moreBreezhaler better than Seretide, says Vectura
5th Sep 2016 07:42
(ShareCast News) - Inhaled airways disease focused pharmaceuticals company Vectura Group confirmed an announcement from its alliance partner Novartis on Monday, that new analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler is a "more effective option" for patients at risk of
Read moreVectura inhaler collaboration with Novartis improves treatment persistence
31st Aug 2016 11:35
(ShareCast News) - Novartis has published data about a respiratory drug combination delivered using an inhaler designed in collaboration with Vectura that shows patients are twice as likely to persist with treatment over 12 months than with a popular product already on the market. Patients using Nov
Read moreInvestec resumes coverage on Vectura at 'buy'
22nd Aug 2016 14:30
(ShareCast News) - Investec resumed coverage on Vectura at 'buy' with a 200p price target following completion of the SkyePharma deal. "In our view, the benefits from a broader royalty base, improved cash flows, as well as an enhanced competency set, are yet to be fully reflected in the share price,
Read moreVectura to receive milestone payment for EXPAREL
5th Aug 2016 07:08
(ShareCast News) - Inhaled airways disease focused company Vectura Group announced on Friday that a sales milestone receipt of $8m has been triggered following confirmation by Pacira Pharmaceuticals that worldwide annual net sales of EXPAREL, on a cash received basis to 30 June, were above $250m. Th
Read more